Category Archives: GeneXpert

Study says healthcare shortcomings leave tuberculosis undiagnosed, untreated

By on .

In a prospective autopsy study published in The Lancet of patients who died at a hospital in Lusaka, Zambia, researchers found a large percentage of patients were infected with tuberculosis but had gone undiagnosed and untreated, and 17 percent of patients infected with tuberculosis were indeed infected with multidrug-resistant TB but also remained undiagnosed. Aiming […]

GeneXpert analysis puts numbers, consistency on test’s advantages

By on .

McGill University researchers who analyzed 18 studies involving more than 7,000 people released findings today showing the GeneXpert rapid diagnostic test for tuberculosis detected the disease among 67 percent of samples in which it had been missed by smear microscopy, the most common diagnostic tool in low-resource but high burden countries. While both tests require […]

PEPFAR adds to investment in rapid TB tests

By on .

The President’s Emergency Plan For AIDS Relief will buy as many as an additional 150 rapid tuberculosis testing devices with materials to test about 450,000 people for tuberculosis, addressing a need to improve diagnoses of drug-resistant strains of disease, and to identify the disease in HIV-positive people in sub Saharan Africa and Myanmar, the Office […]

Haitian prison an incubator for disease, but treatment for multidrug-resistant TB remains out of reach

By on .

When the January 2010 earthquake cracked the walls of Haiti’s National Penitentiary, the roughly 4,500 prisoners caged inside fled into the streets of Port Au Prince. They left a place built to hold about 1,000 men that had gotten so crowded that prisoners shared sheets turned into hammocks, and window ledges for beds, while others, […]

WHO’s TB chief: ‘We have to be bold’

By on .

Dr. Mario Raviglione has been the director of the World Health Organization’s Stop TB Department since 2003. He spoke with John Donnelly about his frustrations with detecting cases of multidrug-resistant TB as well as with delays in accomplishing widespread availablity of the GeneXpert machine, which can detect drug-resistant TB in two hours, compared to two […]

Report: GeneXpert TB diagnostics take off in low-resource countries

By on .

As of the end of the first quarter of 2012, nearly 864,000 GeneXpert MTB/RIF rapid tuberculosis (TB) diagnostic cartridges had been procured under manufacturer Cephied’s concessional pricing mechanism. The information was part of a the three-page report released in May by the Stop TB Department of the World Health Organization (WHO), giving an update on […]

UNITAID seeks innovative HIV, TB and malaria proposals

By on .

UNITAID is inviting letters of intent (LOI), or short conceptual presentations of a proposed project, on the topic of improving access to key preventive, diagnostic and treatment commodities for HIV, tuberculosis (TB) and malaria through market-based approaches.  UNITAID works to negotiate low pricing for diagnostics and medication for AIDS, tuberculosis and malaria in developing countries […]

U.S. is world’s largest funder of global health research and development

By on .

Report shows investments save lives and dollars

The U.S. government invested $12.7 billion over the past decade in the creation of new vaccines, drugs, diagnostics and other products for neglected diseases in the developing world. That’s according to a new report released by the Global Health Technologies Coalition (GHTC) and Policy Cures on Friday.

Of the 45 new products registered in that time to address these neglected diseases that affect more than 1 billion people around the world, the U.S. was involved in the development of 24 of them (or 52 percent).

Tackling TB/HIV co-infection in Africa: An interview with CDC’s Dr. Bess Miller

By on .

Science Speaks continues its interview series exploring the global HIV and tuberculosis research and development efforts at the U.S. Centers for Disease Control and Prevention (CDC) with a conversation with Bess Miller, MD, MSc, who works in the Division of Global HIV/AIDS. Dr. Miller has served as associate director and team lead for HIV/TB, providing leadership in policy and implementation of TB/HIV activities in 43 resource-limited countries supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). She has worked to align PEPFAR TB/HIV priorities with the World Health Organization (WHO) policies on TB/HIV, and on the use of antiretroviral therapy (ART) in people living with HIV (PLHIV). In this interview Dr. Miller discusses the successes and challenges in implementing TB infection control in Africa, progress in deploying the GeneXpert MTB/RIF rapid TB diagnostic on the ground there, and how efforts to scale up access to ART are helping achieve goals in TB control and elimination.

Engaging the private sector to spur global development and save the foreign assistance budget

By on .

Foreign assistance experts gathered Wednesday to discuss the George W. Bush administration’s legacy on global development, focusing on lessons learned and applying them to the next decade and beyond, at an event hosted by the Consensus for Development Reform and the Modernizing Foreign Assistance Network in Washington. The panel discussion revolved around a central theme […]